This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO 2021
ASCO 2021
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ASCO 2021 Prostate Cancer
Viewing 1-20 of 90 articles
ASCO 2021: The Variability in Prostate Cancer Treatments and Outcomes Based on Geographic Location and Race
ASCO 2021: Complementary Detection of Genomic Alterations in Metastatic Castration Resistant Prostate Cancer From CheckMate 9KD Through Analyses of Tumor Tissue and Plasma DNA
ASCO 2021: An Open-Label, Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Dose Oral Docetaxel in Metastatic Prostate Cancer Patients Treated with IV Docetaxel
ASCO 2021: Differences in Toxicity and Outcomes: A Race-based Case Study
ASCO 2021: Genomic Disparities Across Gleason Scores
ASCO 2021: Safety and Efficacy of AMG 160, a Half-Life Extended BiTE Immune Therapy Targeting PSMA, and Other Therapies for Metastatic Castration-Resistant Prostate Cancer
ASCO 2021: Race, Ethnicity, and Cancer Disparities: Ending the Genetic Debate
ASCO 2021: SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy (ADT) plus TAK-700 with ADT plus Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
ASCO 2021: Can We Define the Standard of Therapy for First-Line Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)?
ASCO 2021: Association of Increased Intensity of Prostate-Specific Antigen (PSA) Screening in Younger African American Men with Improved Prostate Cancer Outcomes
ASCO 2021: Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII Trial Combining Radium-223 with Enzalutamide Versus Enzalutamide Alone: An Updated Safety Analysis
ASCO 2021: Are We Making Progress in Addressing Disparities in Prostate Cancer?
ASCO 2021: VanDAAM Study: A Prospective Validation of the Genomic Classifier to Define High-Metastasis Risk in a Subset of African American Men with Early Localized Prostate Cancer
ASCO 2021: First Results of PEACE-1: A Phase 3 Trial with a 2x2 Factorial Design of Abiraterone Acetate plus Prednisone And/or Local Radiotherapy in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
ASCO 2021: Single-Lesion PSMA Protein Expression and Response to Lu-177 PSMA Therapy In Patients With Castration-Resistant Prostate Cancer
ASCO 2021: Real-World First-Line Treatment Patterns in Patients with Metastatic Castration-Sensitive Prostate Cancer in a U.S. Health Insurance Database
ASCO 2021: Long-Term Adverse Events (AE) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Receiving Prostate-Specific Membrane Antigen (PSMA)-Based Targeted Radionuclide Therapy (TRT)
ASCO 2021: Differences in the Pattern of and Response to Treatment: Not Just Race
ASCO 2021: Do Our Treatments Drive a New Resistant Mutational Phenotype?
ASCO 2021: The New Avengers in the Treatment of Prostate Cancer
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free